Satellos Bioscience Inc (MSCLF)

$0.92 +0.01 (1.41%)
Market Cap 171.22M
Revenue (ttm) 0.00
Net Income (ttm) -20.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 352,900
Avg Vol 161,554
Day's Range N/A - N/A
Shares Out 185.51M
Stochastic %K 79%
Beta 1.10
Analysts Strong Buy
Price Target $0.86

Company Profile

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
WBinthehouse
WBinthehouse Feb. 4 at 5:58 AM
$MSCLF ATOS stock consolidated their shares 15-1 on February 2, 2026 and lost 32% on the first trading day post split. Lol Reverse splits often signal distress and can lead to immediate price drops. This ticker is heavy.
0 · Reply
WBinthehouse
WBinthehouse Feb. 4 at 5:40 AM
$MSCLF Satellos Bioscience reported its most recent cash position in the third quarter 2025, financial results ended September 30, 2025, released on November 14, 2025. Cash and cash equivalents, US$19.3 million Short term investments: US$15.3 million Total cash, cash equivalents, and short-term investments. US$34.6 million end of September 2025. Analysts and company statements from earlier 2025 estimated cash runway into 2026 or through key milestones like Phase 2 initiation. However, with burn rates around US $20-21 million annually the runway is likely sometime this year or sooner. Lots of going ons with this company, with the latest consolidation of 15 million shares and a lofty PPS of $12 that used to be 185 million shares with PPS in pennies. The time is ripe for the company to make money in lieu of the brave souls buying this pig. I can see the vultures dressed in bears circling, getting ready to pounce on this for the take down. This is bio where lots get slaughtered. GL.
0 · Reply
WBinthehouse
WBinthehouse Feb. 4 at 3:46 AM
$MSCLF this quote is old, Elijah added when the stock price was in pennies. He didn’t spend over $1 million dollars today. Shame on you for posting inaccuracies.
0 · Reply
Florestan
Florestan Feb. 4 at 3:41 AM
$MSCLF what I want to see: DMD kids walk again. DMD kids run again. DMD adults get off their wheel chairs. And live into old age. What the human garbages want: people continue to decline or wheelchair bound while on their million dollar drugs. Hope that's clear.
0 · Reply
PennyScam
PennyScam Feb. 4 at 2:11 AM
$MSCLF No. Thats brilliant. All that financing not warming your belly. All that money for doing fuck all. Not bad eh. Good in the financier. They really fucked over the small fry trader eh. Fucked them real good. Do you feel bad for traders that don’t use fundamentals to trade? Sorry to hear about your struggles. Hey, you still have ICO Therapeutics. Isn’t that good enough for ya? It should be. It‘s good enough for me. Don't you like Franky Baby? He’s a real class act I’m sure. I will let you know if I start buying. So far I don’t want to. Missed the boat. Or did I? Hope you win big. All the best. Sucks to lose. So I hear. I hear it everywhere these days. Massive shake outs. I try keep doing hand exercises to strengthen those hands. I have this little 30 pound ring that works like a dynamo. Weak hands are brutal especially as you age. Farmers walk can help. CrazyK
1 · Reply
spaceodyssey2001
spaceodyssey2001 Feb. 4 at 2:01 AM
$MSCLF Recent post from Elijah Stacy, who has Duchenne muscular dystrophy, has worked at Capricor $CAPR and Satellos and is the founder of Destroy Duchenne. "Today, I added 100,000+ shares of Satellos $MSCL to my current position! I think this could be a truly revolutionary drug. Let’s go change the world. Exciting times ahead for DMD & regenerative medicine!"
1 · Reply
WBinthehouse
WBinthehouse Feb. 3 at 3:02 AM
$MSCLF Bottom line, consolidated ~800 million shares to 15 million while raising $100 million with only a Phase 1 to show. That’s pretty pathetic.
2 · Reply
spaceodyssey2001
spaceodyssey2001 Feb. 3 at 1:20 AM
$MSCLF 2021: Completed reverse takeover to go public; built muscle stem‑cell platform, MyoReGenX for regenerative treatments in Duchenne muscular dystrophy (DMD) and other muscle diseases. 2022: Advanced and refined proprietary small‑molecule series targeting muscle stem‑cell polarity, moving toward pre‑IND readiness. 2023: Selected SAT‑3247 as lead development candidate for DMD and identified AAK1 as its molecular target with strong preclinical data. 2024: Became clinical‑stage by starting Phase 1 trials of SAT‑3247 in healthy volunteers. 2025–now: Reported favorable Phase 1a safety/PK results and completed Phase 1b trial in adult DMD patients, while extending its platform to other muscle diseases, including FSHD. Long term follow-up trial of Adult DMD patients started Oct 2025. Global Phase 2 pediatric DMD trial starting now.
0 · Reply
HamBoneXoXo
HamBoneXoXo Feb. 2 at 8:00 PM
$MSCLF What’s the deal here? So does this rs adjust? Can’t trade it now.
1 · Reply
WBinthehouse
WBinthehouse Feb. 2 at 6:57 PM
$MSCLF $MSCLF Reverse split 20-1 in 2021. Then dilute $55 million in May 2023, dilute another $40 million in December 2024. Afterwards consolidated 180 million shares 12-1 on January 2025. Yep it’s a dilution machine. Started DMD drug trials in 2018 the same year as CAPR and all Satellos can show is a finished Phase1. lol
0 · Reply
Latest News on MSCLF
No data available.
WBinthehouse
WBinthehouse Feb. 4 at 5:58 AM
$MSCLF ATOS stock consolidated their shares 15-1 on February 2, 2026 and lost 32% on the first trading day post split. Lol Reverse splits often signal distress and can lead to immediate price drops. This ticker is heavy.
0 · Reply
WBinthehouse
WBinthehouse Feb. 4 at 5:40 AM
$MSCLF Satellos Bioscience reported its most recent cash position in the third quarter 2025, financial results ended September 30, 2025, released on November 14, 2025. Cash and cash equivalents, US$19.3 million Short term investments: US$15.3 million Total cash, cash equivalents, and short-term investments. US$34.6 million end of September 2025. Analysts and company statements from earlier 2025 estimated cash runway into 2026 or through key milestones like Phase 2 initiation. However, with burn rates around US $20-21 million annually the runway is likely sometime this year or sooner. Lots of going ons with this company, with the latest consolidation of 15 million shares and a lofty PPS of $12 that used to be 185 million shares with PPS in pennies. The time is ripe for the company to make money in lieu of the brave souls buying this pig. I can see the vultures dressed in bears circling, getting ready to pounce on this for the take down. This is bio where lots get slaughtered. GL.
0 · Reply
WBinthehouse
WBinthehouse Feb. 4 at 3:46 AM
$MSCLF this quote is old, Elijah added when the stock price was in pennies. He didn’t spend over $1 million dollars today. Shame on you for posting inaccuracies.
0 · Reply
Florestan
Florestan Feb. 4 at 3:41 AM
$MSCLF what I want to see: DMD kids walk again. DMD kids run again. DMD adults get off their wheel chairs. And live into old age. What the human garbages want: people continue to decline or wheelchair bound while on their million dollar drugs. Hope that's clear.
0 · Reply
PennyScam
PennyScam Feb. 4 at 2:11 AM
$MSCLF No. Thats brilliant. All that financing not warming your belly. All that money for doing fuck all. Not bad eh. Good in the financier. They really fucked over the small fry trader eh. Fucked them real good. Do you feel bad for traders that don’t use fundamentals to trade? Sorry to hear about your struggles. Hey, you still have ICO Therapeutics. Isn’t that good enough for ya? It should be. It‘s good enough for me. Don't you like Franky Baby? He’s a real class act I’m sure. I will let you know if I start buying. So far I don’t want to. Missed the boat. Or did I? Hope you win big. All the best. Sucks to lose. So I hear. I hear it everywhere these days. Massive shake outs. I try keep doing hand exercises to strengthen those hands. I have this little 30 pound ring that works like a dynamo. Weak hands are brutal especially as you age. Farmers walk can help. CrazyK
1 · Reply
spaceodyssey2001
spaceodyssey2001 Feb. 4 at 2:01 AM
$MSCLF Recent post from Elijah Stacy, who has Duchenne muscular dystrophy, has worked at Capricor $CAPR and Satellos and is the founder of Destroy Duchenne. "Today, I added 100,000+ shares of Satellos $MSCL to my current position! I think this could be a truly revolutionary drug. Let’s go change the world. Exciting times ahead for DMD & regenerative medicine!"
1 · Reply
WBinthehouse
WBinthehouse Feb. 3 at 3:02 AM
$MSCLF Bottom line, consolidated ~800 million shares to 15 million while raising $100 million with only a Phase 1 to show. That’s pretty pathetic.
2 · Reply
spaceodyssey2001
spaceodyssey2001 Feb. 3 at 1:20 AM
$MSCLF 2021: Completed reverse takeover to go public; built muscle stem‑cell platform, MyoReGenX for regenerative treatments in Duchenne muscular dystrophy (DMD) and other muscle diseases. 2022: Advanced and refined proprietary small‑molecule series targeting muscle stem‑cell polarity, moving toward pre‑IND readiness. 2023: Selected SAT‑3247 as lead development candidate for DMD and identified AAK1 as its molecular target with strong preclinical data. 2024: Became clinical‑stage by starting Phase 1 trials of SAT‑3247 in healthy volunteers. 2025–now: Reported favorable Phase 1a safety/PK results and completed Phase 1b trial in adult DMD patients, while extending its platform to other muscle diseases, including FSHD. Long term follow-up trial of Adult DMD patients started Oct 2025. Global Phase 2 pediatric DMD trial starting now.
0 · Reply
HamBoneXoXo
HamBoneXoXo Feb. 2 at 8:00 PM
$MSCLF What’s the deal here? So does this rs adjust? Can’t trade it now.
1 · Reply
WBinthehouse
WBinthehouse Feb. 2 at 6:57 PM
$MSCLF $MSCLF Reverse split 20-1 in 2021. Then dilute $55 million in May 2023, dilute another $40 million in December 2024. Afterwards consolidated 180 million shares 12-1 on January 2025. Yep it’s a dilution machine. Started DMD drug trials in 2018 the same year as CAPR and all Satellos can show is a finished Phase1. lol
0 · Reply
WBinthehouse
WBinthehouse Feb. 2 at 5:36 PM
$MSCLF is this trading as MSCLD. Etrade 500 shares?
1 · Reply
bruceleeboy
bruceleeboy Feb. 2 at 3:02 AM
$IMNPQ.DL0922 $IVF $INVO Dos pure plays. Immune deal with certain assets acquired in addition to Bert by Alexion/ Astra. Cytovia/ Naya kids ripe for merger with a company like $ESHA $MSCLF $ICOTF Immunis (private which does NOT have a designated CEO) or possibly another exciting stranger. Interesting times.
1 · Reply
WBinthehouse
WBinthehouse Feb. 2 at 12:29 AM
$MSCLF here’s a brief summary of Satellos stock consolidation or RS In 2021 the company RS 20-1 and a name change. They started with 660 million outstanding shares. 2021 Post RS the company started with 33 million outstanding shares. After so many raises and warrants, outstanding shares grew to 185 million before last Fridays consolidation. Keep buying lol.
1 · Reply
PennyScam
PennyScam Feb. 1 at 3:12 AM
$MSCLF A financing we will go.…… See ya back at zero. Crazy K
0 · Reply
Florestan
Florestan Jan. 31 at 3:15 AM
$MSCLF noooo they didn't adjust this shit for the RS 😭
0 · Reply
citywokowner
citywokowner Jan. 30 at 9:37 PM
$MSCLF Holding on tight to my measly 433 shares. LFG Satellos
0 · Reply
spaceodyssey2001
spaceodyssey2001 Jan. 30 at 8:15 PM
$MSCLF Encode - https://www.encodelp.com/coverage-universe/with-biotech-risk-on-lets-revisit-gain-satellos/ “ Follow The Money For an OTC/TSX-listed company, Satellos hasn’t had any issues raising funds from U.S.-based deep-science investors. Despite Satellos’s success in raising money, the absence of a proper U.S. listing has clearly limited the trading of its stock. The company has committed to listing on Nasdaq. Once listed on Nasdaq, Satellos, with a valuation of around $100 million and “pivotal” DMD data expected mid-next year, is likely to attract significant investor attention.”
1 · Reply
WBinthehouse
WBinthehouse Jan. 30 at 7:50 PM
$MSCLF this scam use to be for opthamolgy? lol. Lured a lot of suckers for DMD.
1 · Reply
topstockalerts
topstockalerts Jan. 30 at 4:18 PM
$MSCLF Starting to wake up as volume increases. Buyers are getting more aggressive at these levels. Worth keeping this on radar.
0 · Reply
PennyScam
PennyScam Jan. 30 at 3:39 PM
$MSCLF What’s happening with ophthalmology indication? Gleeson needs to talk to Naya Therapeutics. They are wanting an ophthalmology drug. This RS makes things easy. Hey Greasy Gleeson! Call them. Crazy K
1 · Reply
PennyScam
PennyScam Jan. 30 at 3:30 PM
$MSCLF Hilarious. Crazy K
0 · Reply
WBinthehouse
WBinthehouse Jan. 30 at 2:56 PM
$MSCLF what’s the new ticker of this bad boy?
1 · Reply